Figure 5.

PDCs of BMs from diverse primary tumor origins were used to assess the efficacy of PI3K and mTOR inhibitors

(A–L). PDCs were established from surgical BM samples derived from patients with (A)–(C) melanoma, (D)–(F) lung carcinoma, (G)–(I) endometrium cancer, and (J)–(L) colon cancer. (A, D, G, J) Representative western blots demonstrate different patterns of Pi3K and mTOR pathway inhibition after incubation of PDCs with buparlisib and everolimus, respectively. Inhibition of cell proliferation upon treatment with increasing doses of buparlisib (B, E, H, K) and everolimus (C, F, I, L) also show different levels of inhibition among BM-derived PDCs. Cell viability was measured using MTS assay. Data are represented as median with interquartile range, with three technical replicates. Differences were considered statistically significant for p values <0.05, according to the Mann-Whitney test.